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ABSTRACT 
Objective: The goal of the current study was to investigate the possible use of solid lipid nanosuspension (SLNs) as a drug delivery method to boost 
doxorubicin (DOX) brain-targeting performance after intranasal (i. n.) administration.  
Methods: 33 factorial design was applied for optimization by using lipid concentration, surfactant concentration, and High-speed homogenizer 
(HSH) stirring time as dependent variables, and their effect was observed on particles size, Polydispersity index (PDI), and entrapment efficiency.  
Results: With the composition of Compritol® 888 ATO (4.6 % w/v), tween 80 (1.9 % w/v), and HSH stirring time, the optimized formula DOX-SLNs 
prepared (10 min). Particle size, PDI, zeta potential, entrapment efficiency, percent in vitro release were found to be 167.47±6.09 nm, 0.23±0.02, 
24.1 mV, 75.3±2.79, and 89.35±3.27 percent in 24 h, respectively, for optimized formulation (V-O). No major changes in particle size, zeta potential, 
and entrapping efficiency were found in the stability studies at 4±2 °C (refrigerator) and 25±2 °C/60±5% RH up to 3 mo.  
Conclusion: 
Keywords: Solid lipid Nanosuspension, Homogenization and Ultrasonication, Characterization, Factorial design, Nose to brain delivery 
Following the non-invasive nose-to-brain drug delivery, which is a promising therapeutic strategy, the positive findings confirmed the 
current optimized DOX-loaded SLNs formulation. 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
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Currently, the most widely used cancer treatment is through 
chemotherapy administered either by the intravenous or oral route, 
which harms the normal cells more than just the cancerous cells in 
the body and causes many unwanted side effects [1]. 
INTRODUCTION 
Doxorubicin hydrochloride (DOX) is a broad spectrum anthracycline 
anticancer drug administrated intravenously, including the US Food 
and Drug Administration (USFDA) approved pegylated liposomal 
doxorubicin marketed as Doxil® for treatment of numerous human 
cancers [2-4]. No significant improvement in efficiency has been 
found through studies despite the use of Doxil® due to sluggish and 
passive release of the drug [5]. 
Treating brain diseases using hydrophilic drugs like DOX is yet more 
difficult as Blood-Brain Barrier (BBB) restricts the entry of drug and 
prevent their uptake in the brain. Due to BBB, no large molecule can 
reach the brain and less than 2% of small molecules find an entry in 
the brain, creating a huddle in the treatment of many life-
threatening brain diseases, including brain cancer [5]. 
Intranasal administration is a non-invasive way that can deliver drugs 
directly into the brain, bypassing BBB through the trigeminal or 
olfactory pathway. It has been exploited by researchers, followed by the 
advantages of self-medication, ease delivery, avert first-pass metabolism, 
rapid onset, reduction in dose amount when compared to oral route [6]. 
Nanoparticulate-based drug delivery may improve the drug delivery 
to the brain via nasal route. These systems protect the drug from P-
glycoprotein (P-gp) efflux, enzyme, and/or chemical degradation 
with an increase in bioavailability and specific biodistribution [7]. 
Nanotechnology carriers include polymeric-based nanoparticles, 
magnetic-based nanoparticles, ligand-based nanoparticles, lipid-
based nanoparticles, etc.  
Solid Lipid Nanoparticles (SLN) is a submicron lipidic carrier 
entrapping the drug in the lipid core and stabilized with the aid of 
surfactant, co-surfactant, and/or stabilizer.  
The objectives of the current study were to apply an experimental 
design approach in the development of DOX-loaded SLN delivery 
administered via nasal route. The experimental design was applied to 
optimize the independent variables (Concentration of Compritol 888 
ATO, Concentration of tween 80, and High-Speed Homogenizer time) to 
achieve low particle size, low polydispersity index (PDI), and high 
entrapment efficiency (EE). DOX SLN were formulated, optimize, and 
were characterized for physicochemical, morphological, in vitro release, 
and kinetic mechanisms [8, 9]. 
MATERIALS AND METHODS 
DOX was collected from Amneal Pharmaceuticals Ltd (Ahmedabad, 
India) as a gift sample. Apifil, Compritol 888 ATO, Compritol HD5 
ATO, Capryol 90, and Precirol ATO 5 (PA) were collected as gift 
samples from Gattefosse Pvt. Ltd. (Mumbai, India). Stearic acid, 
Tween 80, and Poloxamer-407 (Pol-407) were procured from 
Sigma-Aldrich (Bangalore, India). Hydrogenated soybean 
phosphatidylcholine (HSPC) 50 was collected from the Sun Pharma 
Advanced Research Centre (SPARC, Vadodara) as a gift sample. 
Materials 
Lipid selection is one of the most significant factors in Solid Lipid 
Nanosuspension in deciding the drug's encapsulation performance in 
the lipid. The DOX solubility analysis has been investigated in five 
different lipids viz. Compritol 888 ATO, Compritol HD 5 ATO, Precirol 
ATO 5, Apifil, Stearic acid for determining their potential to solubilize 
DOX. The solubility could not be assessed by the equilibrium technique 
since most of the lipids used were in solid condition. Hence, an 
alternative approach was used, where DOX (20 mg) was placed in five 
separate vials. The lipids were separately heated above their melting 
point and gradually added to the vials until a clear solution of lipids is 
formed. The experiment was performed in triplicate [10].  
Selection of lipid using Solubility study of DOX in different lipids 
SLN was formulated using the process of homogenization and 
ultrasonication. The procedure was consist of taking lipid and drug 
in one part while an aqueous solution of surfactant and stabilizer in 
another part. Drug and lipid mixture was melted above the melting 
point of lipid. An aqueous portion was heated at the same 
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temperature. When both the parts attain an equilibrium, an aqueous 
portion was added incorporated into the lipid phase, followed by 
emulsification by a high-speed homogenizer. The temperature of the 
mixture was maintained constant until complete emulsification 
takes place. After obtaining primary emulsion, the mixture was 
ultrasonicated using an Ultrasonic homogenizer (Probe 
sonicator) (orchid scientific and innovative India Pvt ltd, Ambad, 
Nashik) to obtain Solid lipid-based Nanosuspension (SLNS). 
3
Optimization of variables by applying factorial design 
3
Using Design Expert software (Version 12.0, Stat-ease. Inc., US), the 
factorial design was evaluated and a polynomial equation was 
obtained. In the polynomial equation, the magnitude of the 
coefficients has positive signs showing a consistent output or a 
negative sign indicating a contrasting effect. The most appropriate 
test model (equilibrium, a combination of two, quadratic and cubic 
model) was determined based on the comparison of statistical 
parameters such as the coefficient of variation (CV), the coefficient 
of multiplication (R
 experimental design was used for the optimization and evaluation 
of the relationship between the independent variables [critical 
process parameters (CPP)] viz., X1= lipid concentration, X2= 
surfactant concentration, and X3= High-Speed Homogenizer (HSH) 
time and dependent variables (responses) [Critical Quality Attribute 
(CQA)] such as Y1= Particle size, Y2= Polydispersibility index (PDI) 
and Y3= % Entrapment efficiency (EE) (table 1). Here, Compritol 
888 ATO, Tween 80, and poloxamer 407 were selected as lipid, 
surfactant, and stabilizers, respectively. Drug concentration (2 
mg/ml), HSH speed (10000 rpm) and Poloxamer-407 concentration 
(1% iw/w), sonication amplitude (20%) were set as fix levels. 
2), the multiple coefficients of correction adjusted 
(R2
 
 adjusted), the square residual sum predicted and the 3D 
response surface plot given by Design-Expert software graphically. 
The level of significance was considered at a p-value <0.05. 
Table 1: Selection of variable and their level 
Factor (Independent variable) Levels 
Low(-1) Middle (0) High (+1) 
X1= Compritol ATO 888 (as a lipid) concentration (%w/w) 3 4 5 
X2 = Tween 80 (as a Surfactant) concentration (%w/w)  1.5 2 2.5 
X3=HSH Time (min) 5 10 15 
Response (Dependent variable) Goals 
Y1= Particle size Minimize 
Y2= PDI Minimize 
Y3= % iEE Maximize 
 
To create a design space to ensure the quality of the product you 
want, the impact of each independent CPP on CQA was analyzed. 3
Data optimization and model validation 
3 
factorial design is used in the design space proposal to examine 
process parameters, the answer to the quality attributes of DOX 
SLNs is used. The optimization is carried out using an overlay plot 
(graphical) and desirability (numerical) parameters based on 
finding the particle size, PDI, and higher EE percentage. 
For characterization, optimized 
Characterization of optimized DOX-SLNs 
DOX-SLNs were formulated and they 
were characterized for physicochemical, morphological, in vitro drug 
release, and kinetic studies as shown below:  
The compatibility study between the selected lipid and drug was 
performed by using a Fourier transform-infrared spectro-
photometer 
Compatibility study of lipid and drug 
(FTIR) and Differential scanning calorimetry (DSC). 
FTIR spectroscopy of Doxorubicin hydrochloride, pure lipid 
excipients, and physical mixture (DOX+lipid) was performed using 
the Fourier transform-infrared spectrophotometer (Alpha-model 
Bruker ATR FTIR spectrophotometer). Spectra were scanned at a 
resolution of 4 cm-1 over a wavelength region of 4000 to 400 cm
Fourier transform-infrared spectrophotometer (FTIR) 
-1. 
The process consisted of dispersing KBr samples and compressing 
them into discs by applying a hydraulic press pressure of 5 tons for 
5 min (KBr pellet method). In the light direction, the pellet was 
positioned and the spectrum was collected. 
DSC measurement of Pure Drug Doxorubicin(DOX), Pure Lipid 
excipients and Physical mixture (DOX+Lipid), blank (placebo) SLNs, 
and DOX loaded SLNs formulation was performed with an 
instrument (
Differential scanning calorimetry (DSC) 
Perkin-Elmer Diamond DSC) for measurement of the 
thermotropic transition of lipids. Empty aluminum pans were used 
as reference and samples were carefully placed in another 
aluminum pan. The measurement was done in an inert atmosphere 
within the temperature range of 30 °C to 200 °C, at 5 °C per min. 
The crystallographic structure of DOX, Compritol 888 ATO, the 
physical mixture (drug+lipid), blank SLNs, and DOX-SLNs were 
characterized by X-ray diffraction (XRD) (D8Advance; Bruker Optik 
GmbH, Ettlingen, Germany). Samples were exposed to Cu-Ka 
radiation (40 kV; 40 mA) at a scan rate of 0.02 °/second over the 
2θ/minute range of 5°–50°. 
X-ray diffraction (XRD) 
Photon correlation spectroscopy (PCS; Zetasizer, HAS 3000; Malvern 
Instruments, Malvern, UK)) was performed to determine particle 
size and Polydispersity Index (PDI). DOX SLNs are diluted 10 times 
with double distilled water before measuring the size and PDI. 
Measurements of particle size and PDI were carried out by taking 1 
ml of the diluted formulation into polystyrene cuvettes and 
disposable folded capillary cells at 25 °C, respectively, for zeta 
potential. At a wavelength of 633 nm, dynamic light scattering 
measurements were taken using the helium-neon laser as a light 
source at a scattering angle of 90o, where particle diffusion is 
transformed into particle size due to Brownian motion. In the case of 
zeta potential, particles travel with a velocity related to their zeta 
potential due to the application of an electric field, which is 
determined using a technique called phase analysis light scattering 
and converted to the zeta potential by inbuilt software. 
Particle size and polydispersity index (PDI) and zeta potential 
Transmission electron microscopy (TEM) (JEM-1200, JEOL Co. Ltd., 
Tokyo, Japan) was used to visualize the surface morphology of the 
formulated nanosuspension. A drop of the nanoparticles dispersion was 
finely spread on a copper grid coated carbon with films and negatively 
stained with 2% (w/v) phosphotungstic acid for viewing [11]
Morphological characterization of optimized DOX SLNs 
. 
By taking 10 ml of formulation in a beaker, the pH of the DOX-loaded 
SLN was determined. At room temperature, pH was measured using a 
calibrated digital pH meter (Eutech Instruments, pH tutor, Singapore) 
A pH of optimized DOX SLNs 
To study the Rheological behavior of the SLNs formulation was 
determined using Brookfield viscometer (Expert L series, Fungilab 
Brookfield viscometer). Viscosity determinations were performed at 
50 rpm using spindle TL6 at 25±2 °C. 
The viscosity of optimized DOX SLNs 
The percent EE of formulated DOX SLNs was calculated using the 
method of centrifugation. To obtain lipid nanoparticles, samples were 
Entrapment efficiency (%EE) of DOX SLNs formulated batches  
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collected in centrifuge tubes and centrifuged at 10000 rpm for 20 min 
at room temperature. The supernatant was obtained, diluted with 
methanol appropriately, and analyzed by UV spectroscopy for free 
drug material. %EE was calculated by following equation (1): [12] 
%EE =
Total amount of DOX − Amount of free DOX
The total amount of DOX
… … … … eq (1) 
In vitro 
Using a dialysis bag diffusion technique, 
drug release of optimized DOX SLNs and release kinetics 
mechanism 
in vitro
All the experiments were performed in triplicate. The data obtained 
from the in vitro drug release analysis were adapted to various 
kinetic models viz., zero-order (cumulative drug release percentage 
versus time), first-order (cumulative drug release log remaining 
versus time), Higuchi model (cumulative drug release percentage 
versus square root of time) Hixon Crowell model (cumulative drug 
root remaining versus time) and Korsmeyer-Peppas model (Log 
percent CDR versus log time) [13]. 
 drug release was 
assessed. A total of 5 ml of the sample was taken into a dialysis bag 
and submerged in a beaker containing 200 ml of phosphate-buffered 
saline (pH 7.4) [42] at 37±1 °C for 12 h with continuous stirring 
using a shaking incubator at a speed of 100 rpm (REMI Instruments 
Ltd). An aliquot of 1 ml of dissolving medium was removed at a fixed 
interval and the same volume of fresh medium was applied. Then 
the absorption of withdrawn samples was measured at 480 nm 
against a blank reagent using the UV spectrophotometer (Agilent 
Cary 60 UV-Vis spectrophotometer). Throughout the experiment, 
sink conditions were preserved. 
The stability analysis aimed to determine the effect of the presence 
of formulation additives on the stability of the drug and also to 
determine the physical stability of the formulation prepared under 
storage and relative humidity conditions. Stability tests at 4±2 °C 
(refrigerator), 25±2 °C/60±5 percent RH and 40±2 °C/75±5 percent 
RH in the stability chamber (Oswald Scientific Equipments Pvt. Ltd, 
Mumbai India) were carried out on optimized DOX-SLNs. After 0, 1, 
3, and 6 mo, the sample was extracted and the effects on particle 
size, shape, PDI, zeta potential, and entrapment efficiency were 
determined. 
Stability studies 
RESULTS AND DISCUSSION 
A limiting factor in the formulation of SLNs is the amount of solid 
lipid needed to solubilize the drug. In Solid lipid nanosuspension 
formulation, the amount of lipid required to solubilize the drug is a 
crucial factor as it has a significant impact on the % entrapment 
efficiency. As per the details shown in fig. 1, to conduct the solubility 
analysis, five distinct solid lipids were taken. DOX solubility in 
Compritol 888 ATO required a lower quantity, suggesting higher 
drug solubility. As it has been successfully used in various 
pharmaceutical dosage types, Compritol 888 ATO has attracted 
particular interest. The applicability of Compritol 888 ATO in the 
preparation of aqueous colloidal dispersions such as solid lipid 
microparticles (SLMs), solid lipid nanoparticles (SLNs) and 
nanostructured lipid carriers (NLCs) to capture lipophilic drugs has 
been highlighted in various research studies [14-20]. 















































Fig. 1: Comparison of the amount of lipid required to solubilized DOX 
 
33 
A significant and critical problem in the production of 
pharmaceutical dosage forms is the investigation of an ideal formula 
for the design of medication of the desired quality through minimum 
trials within a short period. In the literature on the development of 
different pharmaceutical dosage types, optimization through 
computer-aided statistical experimental design methodologies has 
been successfully applied [21]. The technique of statistical 
optimization involves designing a series of experiments that will 
calculate the response variables accurately, fitting the data with 
mathematical models, performing sufficient statistical tests to 
choose the best possible model, and producing an optimal response; 
the values of independent formulation variables are calculated. A 
factorial design is one of the common experimental designs used in 




Selection of factors, levels, and Responses of experimental design 
3 factorial was developed to analyze the main effect, the interaction 
effect, and the quadratic effect of three independent variables (CPP) 
on the three responses (CQA). In this case, 30 experiments run were 
performed, and the results were shown in table 2. 
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Table 2: Observed response for size, PDI, and % EE of factorial runs 
Run X1 X2 X3 Y1 Y2 Y3 
VS1 3 1.5 5  252.5±5.29  0.32±0.074   52.1±2.13  
VS2 4 1.5 5  239.1±4.87   0.291±0.022   58.5±1.89  
VS 3 5 1.5 5  279.7±3.43   0.327±0.03  62±1.11  
VS 4 3 2 5  218.9±6.55   0.306±0.051   54.6±2.56  
VS 5 4 2 5  200.6±4.11   0.257±0.029  64±2.44  
VS 6 5 2 5  239.2±5.01   0.325±0.04  71.7±1.21  
VS 7 3 2.5 5  279.2±3.72   0.361±0.036   47.1±1.35  
VS 8 4 2.5 5  285.3±4.36   0.35±0.064   51.2±2.47  
VS 9 5 2.5 5  306.8±5.63   0.393±0.02  61.6±3.12  
VS 10 3 1.5 10  188.2±3.08   0.235±0.05  57.4±2.40  
VS 11 4 1.5 10  165.3±3.51   0.211±0.047   67.2±1.39  
VS 12 5 1.5 10  228.5±4.13  0.27±0.059   73.1±2.78  
VS 13 3 2 10  174.4±5.29   0.25±0.067   65.2±3.29  
VS 14 4 2 10  142.5±2.05   0.201±0.018   74.2±2.87 
VS 15 5 2 10  199.4±1.33   0.278±0.083  79±1.55  
VS 16 3 2.5 10  208.2±2.58   0.307±0.077   52.7±2.31  
VS 17 4 2.5 10  222.1±4.77   0.318±0.045  58.7±3.33  
VS 18 5 2.5 10  239.6±6.63  0.299±0.089  67.5±3.59  
VS 19 3 1.5 15  196.1±5.97  0.423±0.049   43.1±3.54 
VS 20 4 1.5 15  183.9±6.28  0.401±0.09  49.4±2.65 
VS 21 5 1.5 15  246.7±8.39  0.451±0.057   59.8±2.48  
VS 22 3 2 15 191.2±3.99  0.385±0.03  45.2±1.66  
VS 23 4 2 15  171.4±9.25   0.36±0.063   53.5±2.09  
VS 24 5 2 15  225±4.58   0.40±0.087   62±2.98  
VS 25 3 2.5 15  248.7±6.89   0.441±0.091  39.8±3.23  
VS 26 4 2.5 15  261.2±7.15  0.465±0.05   47.2±2.29  
VS 27 5 2.5 15  251.1±4.92   0.446±0.028   55.4±1.73  
VS 28 4 2 10  137.3±7.50  0.187±0.07  77.2±1.19  
VS 29 4 2 10  148±6.25   0.20±0.062   73.6±1.47  
VS30 4 2 10  143.2±4.10  0.208±0.07  71.7±1.56 
Data represent mean±SD, n=3 
 
A quadratic model was fitted into the data of experimental results by 
the use of Design-Expert® Software Version 12. 
The following main criteria are fitted according to the best model:  
1. High F-value,  
2. Low P-value (<0.05),  
3. Insignificant lack of fit,  
4. High R2 (>0.90),  
5. Low standard deviation,  
6. A randomly scatter plot of residuals, and  
7. Whether it can predict well the validation set.  
Data have shown in table 3 indicated that the p-value for all three 
CQA was>0.05 for cubic and quadratic models. 
 
Table 3: Model fit summary of responses 
Response Source Sequential p-value Lack of fit p-value Adjusted R² Predicted R² Remarks 
Linear Size 0.0513 0.0014 0.1568 0.0301  
2FI 0.9424 0.0012 0.0699 -0.3776  
Quadratic <0.0001 0.0644 0.9833 0.9339 Suggested 
Cubic 0.3157 0.0255 0.8950 0.7147 Aliased 
PDI Linear 0.0371 0.0019 0.1779 0.0484  
2FI 0.9056 0.0016 0.0992 -0.3201  
Quadratic <0.0001 0.0704 0.9323 0.9095 Suggested 
Cubic 0.3165 0.0740 0.9391 0.8376 Aliased 
% EE Linear 0.0024 0.0215 0.3329 0.2442  
2FI 0.9602 0.0182 0.2616 -0.0022  
Quadratic <0.0001 0.4174 0.9324 0.9035 Suggested 
Cubic 0.8028 0.3255 0.9190 0.7444 Aliased 
Warning: The Cubic model is aliased. Quadratic models were found to be best fit models for all dependent variables viz., size, PDI, and %EE, and the 
R2
 
values for the quadratic model were found to be 0.9339, 0.9095, and 0.9035 whereas for the cubic model R2 values were 0.7147, 0.8376 and 
0.7444 respectively. These models were evaluated statistically by applying one-way ANOVA (p<0.05). The result of the ANOVA is shown in table 4 
The particle size of factorial runs varied between 137.3 to 306.8 nm 
as shown in the counterplot and 3D response plot in 
Effect of the independent variable on particle size 
The polynomial equations for size 
fig. 2 and 3.  
Size =+145.46+13.90A+16.97B-18.57C-6.96AB 
0.1444AC+0.6196BC+28.53A²+39.95B²+45.73C²-----------equation-2 
Where A, B, C, AB, AC, BC, A2, B2, C2
As shown in equation 2, Positive coefficients of factor A, B, AC, BC, 
A
 in Equation (2) were significant 
model terms.  
2, B2, C2 denotes synergistic effect on particle size, while negative 
coefficients of C, AB denotes antagonistic effect on particle size. The 
Predicted R2of 0.9339 was in reasonable agreement with the 
adjusted R2 of 0.9833, indicating the adequacy of the model to 
predict the response of particle size. 
It was observed that Conc. of Compritol 888 ATO (lipid 
concentration) had a positive effect on particle size (Y1). It was also 
Effect of lipid concentration on particle size 
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observed that as lipid concentration increased, the dispersed phase 
viscosity also increased, resulting in higher-size particle 
agglomeration and reduced homogenization ability. 
As per results shown in table 2 for various experimental runs, as 
the concentration of tween 80 (Surfactant concentration) 
increased from 1.5% to 2.5% w/w, the size was decreasing and 
then with 2.5, it is increased. With increasing concentration of 
tween 80 from 1.5 % to 2.5 % w/w, it showed reduced 
interfacial tension between lipid and aqueous phase, which may 
control the aggregation of lipid particle by facilitating the 
particle partition thereby resulting in lower size [23]. Higher 
surfactant concentrations, as recorded in previous studies, 
effectively stabilize the lipid matrix by forming a steric barrier 
on its surface, thereby preventing aggregation [24]. When 2.5 % 
w/w tween 80 was used, the size was constantly increasing, it 
was observed. This was because the alkyl chain of the surfactant 
molecule covers the lipid particle surface through hydrophobic 
interaction to form a stable lipid matrix during the 
homogenization process. Once this stable matrix has been 
formed, an excess surfactant can cause surfactant particles to 
accumulate on the surface of the stable lipid matrix, causing an 
increase in size in our case [25]. Effect of surfactant concentration on particle size 
Homogenization was performed at 10000 RPM for three different 
time intervals viz., 5, 10, and 15 min. with an increase in HT from 5 
to 10 min, the size was gradually decreasing, while at 15 min size 
was increasing. One of the important techniques for applying kinetic 
energy to achieve a lower size is the speed and time of 
homogenization for which it is used. Applying high kinetic energy for 
longer periods can lead to instability of the lipid structures 
produced, resulting in larger particles being aggregated and formed. 
In contrast to 10 min of HT, the size was higher at 5 min due to 
inadequate homogenization. An optimum homogenization time 
would therefore contribute to the creation of stable particles with a 
uniform distribution of size. 
Effect of HSH time on particle size 
 
Table 4: Anova response size, PDI, and EE 
Response 1: size (nm) SS df MS F-value p-value Remarks 
Model 58875.49 9 6541.72 27.06 <0.0001 significant 
A-Conc. of Compritol 888 ATO 3564.37 1 3564.37 14.74 0.0009  
B-Conc. of Tween 80 5731.70 1 5731.70 23.71 <0.0001  
C-HSH Time 6361.58 1 6361.58 26.32 <0.0001  
AB 601.33 1 601.33 2.49 0.1290  
AC 0.2522 1 0.2522 0.0010 0.9745  
BC 4.76 1 4.76 0.0197 0.8897  
A² 5746.86 1 5746.86 23.77 <0.0001  
B² 11596.89 1 11596.89 47.97 <0.0001  
C² 14764.97 1 14764.97 61.08 <0.0001  
Residual 5318.17 22 241.73    
Lack of Fit 5260.64 19 276.88 14.44 0.0644 not significant 
Pure Error 57.53 3 19.18    
Cor Total 64193.66 31     
Response: 2 PDI SS df MS F-value p value Remarks 
Model 0.1996 9 0.0222 48.46 <0.0001 significant 
A-Conc. of Compritol 888 ATO 0.0012 1 0.0012 2.72 0.1134  
B-Conc. of Tween 80 0.0106 1 0.0106 23.07 <0.0001  
C-HSH Time 0.0391 1 0.0391 85.44 <0.0001  
AB 0.0005 1 0.0005 1.10 0.3064  
AC 0.0001 1 0.0001 0.1959 0.6623  
BC 0.0013 1 0.0013 2.91 0.1022  
A² 0.0080 1 0.0080 17.50 0.0004  
B² 0.0132 1 0.0132 28.93 <0.0001  
C² 0.0926 1 0.0926 202.33 <0.0001  
Residual 0.0101 22 0.0005    
Lack of Fit 0.0098 19 0.0005 6.75 0.0704 not significant 
Pure Error 0.0002 3 0.0001    
Cor total 0.2096 31     
Response: 3 EE % SS df MS F-value p value Remarks 
Model 3248.97 9 361.00 48.49 <0.0001 significant 
A-Conc. of Compritol 888 ATO 1066.48 1 1066.48 143.25 <0.0001  
B-Conc. of Tween 80 85.95 1 85.95 11.55 0.0026  
C-HSH Time 243.47 1 243.47 32.70 <0.0001  
AB 4.33 1 4.33 0.5810 0.4540  
AC 8.14 1 8.14 1.09 0.3071  
BC 4.57 1 4.57 0.6142 0.4416  
A² 6.61 1 6.61 0.8876 0.3564  
B² 401.08 1 401.08 53.87 <0.0001  
C² 1159.94 1 1159.94 155.81 <0.0001  
Residual 163.79 22 7.44    
Lack of Fit 148.18 19 7.80 1.50 0.4174 not significant 
Pure Error 15.61 3 5.20    
Cor Total 3412.75 31     
SS= Sum of squares; df= degree of freedom; MS= Mean square, The probability value (p-value) by the regression analysis is shown in table 3 and the 
F test value is shown in table 4 for the three CQAs with a confidence level of 95%. The large p-value for lack of fit (>0.05) indicates that the lack of fit 
test is insignificant, implying that a significant model correlation existed between the CPP and CQA. 
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Table 5: Lack of Fit Tests particle size, PDI, and %EE 
Response Source Sum of squares df Mean square F-value p-value Remarks 
size Linear 48832.15 25 1953.29 101.86 0.0014  
2FI 48090.42 22 2185.93 113.99 0.0012  
Quadratic 5260.64 19 276.88 14.44 0.0644 Suggested 
Cubic 2986.52 11 271.50 14.16 0.0255 Aliased 
Pure Error 57.53 3 19.18    
PDI Linear 0.1554 25 0.0062 81.10 0.0019  
2FI 0.1521 22 0.0069 90.15 0.0016  
Quadratic 0.0098 19 0.0005 6.75 0.0704 Suggested 
Cubic 0.0055 11 0.0005 6.56 0.0740 Aliased 
Pure Error 0.0002 3 0.0001    
%EE Linear 2040.60 25 81.62 15.69 0.0215  
2FI 2016.59 22 91.66 17.62 0.0182  
Quadratic 148.18 19 7.80 1.50 0.4174 Suggested 
Cubic 109.17 11 9.92 1.91 0.3255 Aliased 
Pure Error 15.61 3 5.20    
 *The selected model should have an insignificant lack-of-fit. 
 
As shown in the counterplot and 3D response plot in fig. 2 and 3, the 
PDI of factorial runs ranged from 0.187 to 0.465. 
Effect of the independent variable on PDI 
The polynomial equations for PDI were as per following;  
PDI=+0.2057+0.0082A+0.0230B+0.0460C-0.0064AB-0.0027AC-
0.0104BC+0.0337A2+0.0427B2+0.1145C2
Where A, B, C, AB, AC, BC, A
-----------equation-3 
2, B2, C2
Positive coefficients of factors A, B, C, A
 in Equation (3) were significant 
model terms.  
2, B2, C2 denote synergistic 
effect on PDI as shown in equation 3, whereas negative coefficients 
of factor AB, BC, AC denote antagonistic effect on PDI. The predicted 
R2 0.9095 was in good agreement with the modified R2
In terms of actual variables, the equation can be used to make 
predictions of the answer for each factor at given levels. Here, for 
each factor, levels should be defined in the original units. 
 0.9323, 
indicating the adequacy of the model for predicting PDI. 
To calculate the relative impact of each factor, this equation should 
not be used because the coefficients are scaled to fit the units of each 
factor and the intercept is not at the center of the design space. 
It was observed that Conc. of Compritol 888 ATO (lipid 
concentration) had a positive effect on PDI (Y2). It was also 
observed that as lipid concentration increased, the dispersed phase 
viscosity also increased, resulting in greater PDI due to particle 
agglomeration and reduced homogenization ability. 
Effect of lipid concentration on PDI 
As per the results shown in table 2 for different experimental runs, 
PDI decreased as the concentration of tween 80 (surfactant 
concentration) increased from 1.5 % to 2.5 % w/w. With an 
increased concentration of tween 80 from 1.5 to 2.5 % w/w, 
decreased interfacial tension between lipid and aqueous phase was 
shown to regulate lipid particle aggregation by facilitating particle 
partition, resulting in lower PDI [23]. It was observed that PDI 
increased continuously when 2.5 % w/w tween 80 was used, 
Effect of surfactant concentration on PDI 
For three separate time intervals, viz., 5, 10, and 15 min, 
homogenization was performed at 10000 RPM. PDI decreased 
gradually with an increase in HT from 5 to 10 min, while PDI 
increased gradually at 15 min. 
Effect of HSH time on PDI 
As shown in the counterplot and 3D response plot in fig. 2 and 3, the 
% EE of factorial runs ranged from 39.8 to 79. 
Effect of the independent variable on % entrapment efficiency 
(EE %) 
The polynomial equations for %EE were as per following;  
% Entrapment Efficiency (EE %)=+72.88+7.61A-2.08B-3.63C+ 
0.5906AB+0.8203AC+0.6073BC-0.9674A2-7.43B2-12.82C2




As shown in equation 4, the positive factor A, AB, BC, AC coefficients 
denote a synergistic effect on percent EE, while the negative factor B, 
C, A
 in Equation (4) were significant 
model terms.  
2, B2, C2 coefficients denote an antagonistic effect on percent EE. 
The predicted R2 0.9035 was in good agreement with the modified 
R2 0.9324 suggested the adequacy of the model for forecasting the % 
EE response. 
It was observed that Conc. of Compritol 888 ATO (lipid 
concentration) had a positive effect on % EE (Y3). It was also 
observed that as lipid concentration increased, the viscosity of the 
dispersed phase also increased, resulting in decreased 
homogenization efficiency of particle agglomeration. The higher % 
EE may be due to the presence of higher lipid concentrations, which 
provide additional space for the drug molecule to be embedded, thus 
reducing the overall surface area. As the viscosity of the lipid phase 
is higher and thus shows higher %EE [26, 27], this can lead to a 
reduction in the diffusion rate of the solute molecule. From the 
outcome shown in table 4, it was observed that 3% lipid 
concentration showed weak % EE of 39.8±3.23 compared to 5% 
lipid concentration showing more than 55 % EE in all experimental 
runs because lipid quantity was higher. 
Effect of lipid concentration on % EE 
As shown in table 2 for different experimental runs, as the 
concentration of tween 80 (surfactant concentration) increased 
from 1.5% to 2.0% w/w, EE percent increased. It was found that 
the percent EE was reduced when 2.5 percent w/w tween 80 was 
used. The reduction in EE percent could be due to a higher 
solubilization effect produced by a higher DOX surfactant 
concentration. DOX solubility in the external phase can increase at 
higher surfactant concentrations due to the diffusion of the drug 
from the lipid core into the aqueous phase, resulting in a 
decreased % EE. The findings were consistent with the results of 
another group describing a lower EE percentage, which may be 
attributed to the solubilization effect of the emulsifier on the 
aqueous phase drug molecule [27].  
Effect of surfactant concentration on % EE 
The % EE was found to be lower in 15 min than in 10 min. This was 
attributable to the removal from the lipid surface of surfactant 
particles, which induced lipid disruption and the escape of the 
trapped drug into the aqueous process. 
Effect of HSH time on % EE 
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Fig. 2: Counter plot with the effect of formulation and process variable on A) Particle size B) PDI C) %EE 
 
 
Fig. 3: 3D response surface plot with the effect of formulation and process variable on A) Particle size B) PDI C) %EE 
Shah et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 5, 45-57 
52 
To create new formulations with the desired response (optimum 
quality), a numerical optimization method using the desirability 
approach was used. The desired ranges of in dependable variables 
(factors) were limited to 3≤A≤5 % 1.5 ≤B≤ 2.5 %, and 5 ≤C≤ 15 min, 
while the desired response ranges were limited to 200≤Y1≤100 nm, 
0.15≤Y2≤0.3, and 70≤Y3≤ 80 %. The optimum response values were 
obtained by numerical analysis using the Design-Expert 12 software 
and one of them was chosen based on the desirability criterion. 
Optimization of data and validation of response surface 
methodology 
Optimized DOX loaded Solid Lipid-based Nanosuspension (SLNs) 
optimized process variable settings proposed by design were 
prepared using the homogenization and ultrasonication to evaluate 
the optimization capability of the mathematical models produced 
according to the results of the complete 33
By formulating and characterizing nanoparticles at the checkpoint 
batch suggested by the software, experimental validation of DoE 
trials for formulation variables was carried out. The overlay plot 
showing the design space and configured parameters as a 
checkpoint proposed by DoE software to obtain the desired 
responses is shown in fig. 4. 
 factorial design. 
 
Fig. 4: The overlay plot indicating the region of optimal process 
variable settings
 
Table 6: Result of an experiment for confirming optimization capability 
Code Factor 
Conc. of compritol 888 ATO A (%) Conc. of tween 80 B (%) HSH time C (Min) 
V-O 4.6 1.9 10 
Response Predicted value s aObserved Value b
Y1= Particle size (nm) 
Residual 
167.339 167.47±6.09  -0.12 
Y2= PDI 0.220616 0.23±0.02 0.01 
Y3= Entrapment efficiency (%) 77.6838 75.3±2.79 2.38 
aObserved response values: mean±SD (n = 3)., b
 
Residual= [difference between predicted value and actual value], The chosen optimal process 
variable setting used for the optimized formulation was Conc. Compritol 888 ATO (A)= 4.6%, Conc. Tween 80(B)= 1.9% and time (C) of HSH = 10 
min. Optimized DOX-Loaded lipid-based Nano suspension (V-0) formulation was evaluated for response Y1: Particle size (nm), Y2: PDI, and Y3: 
Entrapment efficiency (%). 
Table 7: Point prediction confirmation table 






Observed Std Dev n SE pred 95% PI low Data 
mean 
95% PI high 
Size 167.339 167.339 167.47 15.5478 3.00 10.69 145.153 167.47 189.525 
PDI 0.220616 0.220616 0.23 0.0214 3.00 0.0147 0.190091 0.23 0.25114 
EE 77.6838 77.6838 75.3 2.72851 3.00 1.877 73.7904 75.3 81.5773 
*
 
Interval: Two-sided, Confidence = 95%, alpha= 0.05, The observed values (particle size167.47±6.09 nm, PDI 0.23±0.02, and EE 75.3±2.79%) were 
comparable to the expected values (particle size 167.33. nm, PDI 0.22, and EE 77.68%) to assess the optimization procedure's reliability. 
Characterization of optimized DOX-SLNs formulation 
The FTIR spectra over the range of 400–4000 cm-1 for DOX, 
Compritol 888 ATO, and physical mixture of DOX and Compritol 888 
ATO are shown in fig. 5. 
Fourier transform infrared (FTIR) spectroscopy 
Important peaks at 3453.59 cm-1 and 3286.90 cm-1 appeared the 
characteristic peak of NH3+Stretching, O-H stretching, H-Bonding, at 
2883.64 cm-1 alkane CH group stretch, at 1736.32 cm-1and 1728.94 
cm-1 carboxylic acid C=O stretch, at 1173.46 cm-1 and 1104.88 cm-1 
C-O stretches. In the FTIR spectrum of physical mixtures of DOX and 
Compritol 888 ATO, these characteristic peaks of DOX were also 
observed without any distinct changes. This reality confirmed that 
no chemical reaction had taken place between the drug and the 
polymer. Compritol 888 ATO was selected as the lipid for preparing 
solid lipid nanosuspension based on a drug lipid solubility and drug 
lipid compatibility analysis. 
Compatibility studies of drug polymers are very essential before 
formulation design DSC helps to provide useful information about 
Differential scanning calorimetry (DSC) 
crystallite and amorphism of the prepared sample. Perkin-Elmer 
Diamond DSC was used to investigate the melting and recrystallization 
behavior of the SLNs. DSC thermograms of doxorubicin, doxorubicin-
loaded SLNs, Blank (Placebo) SLNs, physical mixture (DOX and lipid), 
Compritol 888 ATO, are presented in 
Doxorubicin exhibited an endotherm corresponding to its MP at 
∼235 °C. The thermal curve of the Compritol 888 ATO exhibited an 
endothermic peak at ∼69 °C. Whereas, physical mixture (DOX and 
lipid) exhibited a sharp endothermic peak at ∼68 °C and a very small 
peak was found at about 234 °C, which was present in DOX. The 
melting endotherm of Compritol 888 ATO in blank SLNs and DOX 
SLN formulation was observed at 68.03 °C and 66.06 °C, 
respectively. DSC thermograms of a physical mixture of DOX+Lipid 
and bulk lipid exhibited a melting endotherm corresponding to the 
melting of DOX at ∼65 °C, which was present in DOX-SLNs. However, 
the DOX peak was lost in DOX SLNs [fig. 6. (a) and i(e)]. It could be 
deduced that DOX in SLNs was in an amorphous state [28].  
fig. 6. 
X-ray diffraction (XRD
XRD patterns of DOX, Compritol 888 ATO, the physical mixture 
(drug+lipid), blank SLNs, and DOX-SLNs are shown in fig. 7. 
) 
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Fig. 5: IR spectra of DOX, compritol 888 ATO 88, and physical mixtures of DOX and compritol 888 ATO 
 
 
Fig. 6: DSC Thermogram (a) doxorubicin (DOX) (b) Compritol 888 (c) Physical mixture (DOX+Lipid) (d) Blank SLNs (e) DOX SLNs 
 
 
Fig. 7: X-ray diffraction patterns DOX, Compritol 888 ATO, the physical mixture (drug+lipid), blank SLNs, and DOX-SLNs 
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At scattered angles, DOX's XRD patterns displayed sharp peaks, 
ranging from 15° to 25°, suggesting their crystalline existence. 
Light diffraction peaks of DOX were observed in the physical 
mixture at around 16 °, showing incomplete dissolution and the 
presence of a crystalline state of both drugs in bulk lipid. The 
blank SLN and DOX-SLNs XRD patterns were wider and much 
weaker than the bulk lipid. There were no characteristic peaks in 
DOX-SLNs for DOX, however, indicating the amorphous state of 
DOX. The XRD result of these DOX-SLNs was following that of the 
DSC. 
Particle size distribution and zeta potential curve of optimized 
formulation (V-O) were shown in fig. 8 (a,b), respectively 
Particle size, PDI, and zeta potential  
 
 
(a) Plot for the size distribution vs number for batch V-O (n=3) 
 
(b) Plot of zeta potential distribution for the batch V-O (n=3) 
Fig. 8: (a) Particle size distribution curve, (b) zeta potential curve of optimized formulation 
 
The average particle size of the optimized formulation was 
167.47±6.09 nm, which was found to be sufficient for nasal 
pathway brain targeting. In essence, PDI is the ratio of the 
standard deviation to the mean size of particles. A PDI value of 0.3 
or less suggests particle size uniformity. In this case, the PDI value 
of the formed SLNs was found to be 0.23±0.02, suggesting 
uniformity in particle size. In the dispersion of SLNs, the zeta 
potential shows the degree of charge present on suspended 
particles. A suitably high zeta potential value (30mV to-30 mV) 
confers stability since aggregation is resisted by particles. The zeta 
potential (24.1 mV) value of the optimized formulation of SLNs 
showed good stability [29]. 
Morphological inspection of DOX SLNs using TEM analysis 
showed that SLNs were spherical (fig. 9) and were in the size 
range of 150-200 nm, which was based on the dynamic light 
scattering theory, in further agreement with the size distribution 
performed using Zetasizer. From fig. 9 It was noted that the 
particles of the SLNs had a uniform distribution of size, 
confirmed by Zetasizer, showing a PDI value below 0.25, 
suggesting no aggregation. 
Morphological study 
 
Fig. 9: TEM image of optimized DOX-SLNs formulation 
 
The entrapment efficiency of optimized 
Entrapment efficiency (%) 
DOX SLNs formulation was 
found to be 75.3±2.79. 
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The optimized formulation of DOX SLNs showed a pH value of 
5.86±0.35, which was within the standard pH range of 5-6.5 for 
human nasal mucosa and thus does not cause nasal inflammation 
when administered intranasally [30]. 
pH 
The viscosity values for the optimized formulation of DOX-loaded 
SLNs were 39.5±0.93 cP, which was lower than 50 cP, thus ensuring 
strong intranasal administration tolerance. Formulation with a 
higher viscosity value often results in increased residence time but 
faces administration difficulties and may display decreased 
absorption due to reduced drug diffusion from the formulation, 
whereas systems with lower viscosity can be easily administered 
but have to face faster MCC, thus reducing the contact time of the 
mucosa formulation applied [31]. 
Viscosity 
A comparative 
In vitro drug release study 
in vitro
The optimized DOX SLNs showed an initial release of 8.43±1.49 
percent, compared to 8.13±1.52 percent after 1 h for commercially 
available DOX liposomal preparation. Optimized DOX SLNs 
subsequently showed sustained drug release with a cumulative drug 
release of 89.35±3.27 percent over 24 h, while Marketed DOX 
Liposomal preparation showed 94.9±4.64 percent over 24 h. An f2 
parameter is widely used to determine the similarity of two 
dissolution profiles. To show the similarity between two dissolution 
profiles, a public norm of f2 value between 50-100 is used. In our 
case, the similarity factor f2=98.33 indicates that the similarity 
between the optimized DOX-SLNs formulation dissolution profile 
and the marked Dox liposomal preparation is identical. 
 release analysis was conducted between the 
commercialized liposomal preparation of DOX and the optimized 
formulation of DOX-SLNs (V-O). In figure.10. the comparative 
dissolution profile was shown. The DOX-SLNs dissolution profile 
showed an initial burst release, followed by a gradual release. The 
initial burst release may be attributed to the presence of free drugs 
on the surface of particles in the external phase and adsorbed drugs, 
whereas the slow release may be due to the encapsulated drug 
inside the lipid matrix [32]. 
Optimized doxorubicin-loaded lipid nanosuspension (
Analysis of kinetics and mechanism of drug release for 




formulations were fitted into various kinetic models. The correlation 
coefficient (R2) and exponent values of various kinetic models are 
shown in table 8. 
 
Fig. 10: Comparison of % in vitro drug release profile of 
optimized DOX-LNs with marketed DOX liposomal preparation 
 
The results showed that the kinetic models that could be used to 
characterize the release characteristics of doxorubicin-loaded lipid 
nanosuspension (DOX-SLNs) formulations were better suited to the 
zero-order model. The zero-order kinetics model had the highest 
correlation coefficients (R2= 0.982) compared to other kinetic 
models. Diffusion of the drug from the lipid matrix has therefore 
been proposed to be the possible mechanism of action. The value of 
release exponent "n" was found to be 0.4597 in the Korsmeyer-
Peppas model, which seems to suggest the process of release 
regulated by diffusion, so-called Fickian diffusion. Similar results 
have been observed in Shazly [33], who prepared ciprofloxacin-
loaded SLNs. 
Table 8: Release kinetic models for the optimized DOX-SLNs formulation 
Optimized 
DOX-SLNs 
Zero-order First-order Higuchi model Hixon Crowell model Korsmeyer–peppas 
R2 K0 (h–1) R2 K0 (h–1) R2 K0 (h–1) R2 K0 (h–1) R2 n value 
V-O 0.982 3.64 0.956 0.03 0.973 21.43 0.98 0.09 0.8561 0.4597 
 
Table 9: Characteristics of DOX-SLNs after 3-month stability studies at different conditions 
Stability studies 





Particle size (nm)a PDI Zeta potential (mV)a Entrapment efficiency (%)a 
4±2 0 167.47±6.09 0.23±0.02 24.1±1.7 75.3±2.79 
1 169.94±5.82 0.272±0.03 23.3±1.2 75.54±1.20 
3 171.65±2.54 0.284±0.05 22.6±1.5 75.23±1.94 
25±2/60±5 0 167.47±6.09 0.23±0.02 24.1±1.7 75.3±2.79  
1 167.21±3.71 0.226±0.02 23.2±1.2 75.65±1.24 
3 174.76±5.57 0.287±0.03 22.5±1.3 74.78±1.98 
40±2/75±5 0 167.47±6.09 0.23±0.02 24.1±1.7 75.3±2.79  
1 174.45±2.81 0.285±0.04 20.2±1.9 75.39±2.85 
3 355.35±3.98 0.422±0.03 16.6±2.3 74.53±1.27 
aData was expressed as mean±SD, n=3; P<0.05 (measurements obtained at each point in time (1 and 3 mo) at the same storage condition were 
compared with measurements obtained at that storage condition at zero months. There has also been a comparison of various parameters between 
different temperatures), No substantial difference in particle size was observed when stored at 4±2 °C (refrigerator) and 25±2 °C/60±5 percent RH, 
but when stored at 40±2 1C/75±5 percent RH due to aggregation, the particle size increased (P<0.05, table 9). There was a substantial shift between 
4±2 °C (refrigerator) and 25±2 °C/60±5 percent RH, but the zeta potential fell to 40±2 1C/75±5 percent RH (P<0.05). Zeta potential plays an 
important role in physical stability [35]. This may be due to lipid coating dissolution that contributes to particle aggregation. 
 
A lipid nanoparticulate drug delivery system (SLNs) of doxorubicin 
was proposed for brain targeting through intranasal delivery in the 
present research work. SLNs were prepared by the homogenization 
and ultra-sonication process and evaluated for particle size, particle 
size distribution (PDI), zeta potential, entrapment efficiency, in vitro 
release, and stability studies. It was noticed that all measurements 
CONCLUSION 
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were in an acceptable range. To prepare solid lipid nanoparticles of 
reproducible sizes in the range of 137.3 to 306.8 nm by addressing 
the effects of processing parameters, high-speed homogenization 
followed by ultrasonication technique was used. The 33factorial 
design application proved to be a useful method for optimizing DOX-
loaded SLNs. Using a factorial design, the required formulation 
composition can be selected to obtain DOX-loaded SLNs smaller than 
200 nm, depending on the application of the brain targeting system 
through intranasal delivery. The use of 33 full-factor designs allowed 
the production of an appropriate formulation using the minimum 
amount of raw materials and a minimum of time. In vitro drug 
release over 24 h was found to be 89.35±3.27 percent, suggesting a 
controlled and sustained DOX-SLN release profile. No major changes 
in particle size, zeta potential, and entrapping efficiency were 
observed in the stability studies at 4±2 °C (refrigerator) and 25±2 
°C/60±5 percent RH for up to 3 mo. This study, therefore, 
demonstrated the usefulness of SLNs for the delivery of doxorubicin 
via the intranasal (i. n) route to the brain. 
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